Market Trends of Cell Therapy Industry
This section covers the major market trends shaping the Cell Therapy Market according to our research experts:
The Allogeneic Therapies Segment is Expected to Account for a Significant Share in the Cell Therapy Market
Allogeneic therapies rely on a single source of cells to treat many patients. They increase the risk of eliciting an immune response within a patient, and immunosuppressive therapies are sometimes administered in combination with allogeneic products. Therefore, the increasing inclination of physicians toward the therapeutic use of allogeneic therapies and rising awareness about the use of cord cells and tissues across various therapeutic areas are some of the major factors driving the growth. Allogenic cells have benefits as they produce their own immune stem cells that kill the cancer cells that remain even after high-dose treatment with cytotoxic drugs. This response is called a graft-versus-cancer effect, and this is used in the prevention or treatment of cancer relapse. The aforementioned factors are expected to drive the market over the forecast period.
The rising number of clinical trials required to gain regulatory approval for new medications to advance patient care is expected to boost the segment growth. For instance, ALLO-501, ALLO-501A, ALLO-715, UCART19, and UCART19 by Allogene provide growth opportunities for the segmental growth.
Moreover, in January 2020, Allogene Therapeutics Inc. and SpringWorks Therapeutics Inc. entered a clinical trial collaboration agreement for the evaluation of ALLO-715, along with Nirogacestat, in multiple myeloma patients.
Thus, owing to the rising number of research studies on allogenic therapy for cancer and associated benefits, the studied segment is anticipated to register steady growth over the forecast period.
North America is Expected to Dominate the Market Over the Forecast Period
North America is estimated to retain the largest share of the cell therapy market due to the presence of a strong regulatory framework to promote cellular therapy development, the existence of industry key players, and the presence of leading universities that support the research activities in the United States. Factors attributing to the high growth of the market in the region include the increasing prevalence of chronic conditions, rising adoption of regenerative medicine, and rise in the number of clinical studies about the development of cellular therapies.
Rising investments from market players for the development and expansion of cell-based therapies in the United States are expected to drive the market in North America. For instance, in January 2022, Cellino Biotech, an autonomous cell therapy manufacturing company, raised USD 80 million Series A financing round. Cellino plans to expand access to stem cell-based therapies with the intention to build the first autonomous human cell foundry in 2025. The applications of stem cell technologies in the treatment of diseases have ultimately increased the overall adoption rate of these technologies across the world. This has led to increased investments by market players in the development of novel therapies in this area.
Furthermore, improved results of cell therapy products for the treatment of cancers will lead to a rise in product development, which is expected to drive the growth of this market. For instance, in June 2021, Gilead's Yescarta CAR T-cell therapy improved event-free survival by 60% in second-line relapsed or refractory large B-cell lymphoma patients. In addition, in June 2021, Bristol-Myers Squibb reported positive topline results from the phase 3 TRANSFORM Trial evaluating Breyanzi (lisocabtagene maraleucel) in second-line relapsed or refractory large B-cell lymphoma.
Therefore, rising investments and research initiatives by the key market players and positive results of cell therapies are the factors expected to drive the growth of this market in North America.
